Login / Register
MS Validated Antibodies - Logo
  • About us
  • Products
    • Primary antibodies
    • Gallery
  • Distributors
  • Validation
    • Tissue Microarrays
  • Publications
    • Large Scale Studies
    • Further Publications
    • Events
    • Quiz
  • Contact
  • About us
  • Products
    • Primary antibodies
    • Gallery
  • Distributors
  • Validation
    • Tissue Microarrays
  • Publications
    • Large Scale Studies
    • Further Publications
    • Events
    • Quiz
  • Contact
×

Cancer Tissue Gallery SATB2

Path Created with Sketch.
Go to SATB2 Normal Tissue GalleryGo back to Product Page
Bone - Osteosarcoma showing a moderate to strong SATB2 positivity of tumor cells.
Bone – Osteosarcoma showing a moderate to strong SATB2 positivity of tumor cells.
Bone - Osteosarcoma with strong SATB2 immunostaining of all tumor cells.
Bone – Osteosarcoma with strong SATB2 immunostaining of all tumor cells.
Breast - SATB2 negative invasive breast cancer of no special type (NST).
Breast – SATB2 negative invasive breast cancer of no special type (NST).
Breast - SATB2 negative invasive lobular breast cancer.
Breast – SATB2 negative invasive lobular breast cancer.
Colon - Colorectal adenocarcinoma exhibiting only a weak SATB2 immunostaining of tumor cells.
Colon – Colorectal adenocarcinoma exhibiting only a weak SATB2 immunostaining of tumor cells.
Colon - Colorectal adenocarcinoma showing strong SATB2 immunostaining of all tumor cells.
Colon – Colorectal adenocarcinoma showing strong SATB2 immunostaining of all tumor cells.
Colon - Colorectal adenocarcinoma with strong SATB2 positivity of tumor cells.
Colon – Colorectal adenocarcinoma with strong SATB2 positivity of tumor cells.
Colon - Colorectal adenoma with intense SATB2 immunostaining of tumor cells.
Colon – Colorectal adenoma with intense SATB2 immunostaining of tumor cells.
Colon - Neuroendocrine tumor showing strong SATB2 positivity of tumor cells.
Colon – Neuroendocrine tumor showing strong SATB2 positivity of tumor cells.
Esophagus - Adenocarcinoma showing a moderate to strong SATB2 staining of tumor cells.
Esophagus – Adenocarcinoma showing a moderate to strong SATB2 staining of tumor cells.
Esophagus - Adenocarcinoma with a weak to moderate SATB2 positivity of tumor cells.
Esophagus – Adenocarcinoma with a weak to moderate SATB2 positivity of tumor cells.
Esophagus - Squamous cell carcinoma depicting a strong SATB2 positivity of the majority of tumor cells.
Esophagus – Squamous cell carcinoma depicting a strong SATB2 positivity of the majority of tumor cells.
Kidney - Oncocytoma exhibiting a moderate SATB2 immunostaining of a fraction of tumor cells.
Kidney – Oncocytoma exhibiting a moderate SATB2 immunostaining of a fraction of tumor cells.
Kidney - Papillary renal cell carcinoma showing moderate SATB2 immunostaining of tumor cells.
Kidney – Papillary renal cell carcinoma showing moderate SATB2 immunostaining of tumor cells.
Kidney - Papillary renal cell carcinoma showing weak SATB2 immunostaining of tumor cells.
Kidney – Papillary renal cell carcinoma showing weak SATB2 immunostaining of tumor cells.
Kidney - SATB2 negative clear cell renal cell carcinoma.
Kidney – SATB2 negative clear cell renal cell carcinoma.
Kidney - SATB2 negative papillary renal cell carcinoma.
Kidney – SATB2 negative papillary renal cell carcinoma.
Liver - SATB2 negative cholangiocellular carcinoma.
Liver – SATB2 negative cholangiocellular carcinoma.
Lung - SATB2 negative adenocarcinoma.
Lung – SATB2 negative adenocarcinoma.
Lymph node - SATB2 negative diffuse large B-cell lymphoma.
Lymph node – SATB2 negative diffuse large B-cell lymphoma.
Ovary - SATB2 negative clear cell carcinoma.
Ovary – SATB2 negative clear cell carcinoma.
Ovary - SATB2 negative serous high-grade carcinoma.
Ovary – SATB2 negative serous high-grade carcinoma.
Pancreas - Neuroendocrine tumor showing a faint SATB2 immunostaining of tumor cells.
Pancreas – Neuroendocrine tumor showing a faint SATB2 immunostaining of tumor cells.
Pancreas - SATB2 negative ductal adenocarcinoma.
Pancreas – SATB2 negative ductal adenocarcinoma.
Prostate - SATB2 negative adenocarcinoma (Gleason 3+3=6).
Prostate – SATB2 negative adenocarcinoma (Gleason 3+3=6).
Salivary gland - SATB2 negative pleomorphic adenoma.
Salivary gland – SATB2 negative pleomorphic adenoma.
Skin - Merkel cell carcinoma showing a moderate to strong SATB2 immunostaining of all tumor cells.
Skin – Merkel cell carcinoma showing a moderate to strong SATB2 immunostaining of all tumor cells.
Soft tissue - Leiomyosarcoma showing a faint SATB2 immunostaining of most tumor cells.
Soft tissue – Leiomyosarcoma showing a faint SATB2 immunostaining of most tumor cells.
Stomach - Gastric adenocarcinoma (diffuse type) showing a weak to moderate SATB2 immunostaining of tumor cells.
Stomach – Gastric adenocarcinoma (diffuse type) showing a weak to moderate SATB2 immunostaining of tumor cells.
Stomach - Gastric adenocarcinoma exhibiting a weak to moderate SATB2 positivity of tumor cells.
Stomach – Gastric adenocarcinoma exhibiting a weak to moderate SATB2 positivity of tumor cells.
Stomach - SATB2 negative gastrointestinal stromal tumor (GIST).
Stomach – SATB2 negative gastrointestinal stromal tumor (GIST).
Testis - SATB2 negative seminoma.
Testis – SATB2 negative seminoma.
Thyroid - SATB2 negative medullary cancer.
Thyroid – SATB2 negative medullary cancer.
Urinary bladder - Muscle-invasive urothelial carcinoma exhibiting a moderate SATB2 immunostaining of a fraction of tumor cells.
Urinary bladder – Muscle-invasive urothelial carcinoma exhibiting a moderate SATB2 immunostaining of a fraction of tumor cells.
Urinary bladder - Small cell carcinoma with a moderate intensity SATB2 immunostaining of the majority of tumor cells.
Urinary bladder – Small cell carcinoma with a moderate intensity SATB2 immunostaining of the majority of tumor cells.
Urinary bladder - SATB2 negative muscle-invasive urothelial carcinoma.
Urinary bladder – SATB2 negative muscle-invasive urothelial carcinoma.
Uterus - Endometroid endometrium carcinoma with weak to moderate SATB2 immunostaining of the majority of tumor cells.
Uterus – Endometroid endometrium carcinoma with weak to moderate SATB2 immunostaining of the majority of tumor cells.
Uterus, cervix - SATB2 negative squamous cell carcinoma.
Uterus, cervix – SATB2 negative squamous cell carcinoma.
  • Linkedin
  • My Account
  • Search
    ×
  • Cart 0
© 2025 MS Validated Antibodies
  • Imprint
  • Privacy Policy
  • Distributors